Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Quidel Expects SARS-CoV-2 Testing Demand to Continue 'Through 2022, and Beyond'

Quidel Expects SARS-CoV-2 Testing Demand to Continue 'Through 2022, and Beyond'

Oct 30, 2020
|
Madeleine Johnson
Premium

NEW YORK – After reporting on Thursday a near-quadrupling year over year in its third quarter revenues, Quidel CEO Douglas Bryant said on a conference call that the company continues to increase its manufacturing capacities for tests and instruments, and it expects high demand is likely to continue through 2022.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Analysis for the Long Term

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

Pricey, But Available

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Pilot Cancer Testing Program for Taiwan

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

PLOS Papers on TB Resistance, Squamous Cell Carcinoma Risk, MicroRNAs in SCC

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.

What's Popular?

In Business News

  1. Agilent Charges Into Liquid Biopsy Space with Resolution Biosciences Acquisition

    Premium

  2. Spatial Omics Firms Use AGBT as Launchpad for New Tech

    Premium

  3. Fulgent Genetics Aims to Use COVID-19 Testing Gains to Grow Clinical Sequencing Business

    Premium

  4. Illumina Receives Medical Device Registration in Russia for NextSeq 550 Dx Sequencer, Reagents

  5. Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.